The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated analysis of HERBIS-1: A phase ll study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer.
Makio Gamoh
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Naotoshi Sugimoto
Honoraria - Osaka GI-Cancer meeting
Research Funding - The meeting of HER-2 positive gastric cancer
Hiroto Miwa
No relevant relationships to disclose
Masahiro Tsuda
No relevant relationships to disclose
Shinichi Nishina
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Hiroshi Imamura
No relevant relationships to disclose
Jin Matsuyama
No relevant relationships to disclose
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Yukinori Kurokawa
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Yoshito Komatsu
Honoraria - Chugai Pharma; Otsuka; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Otsuka; Taiho Pharmaceutical
Toshimasa Tsujinaka
Honoraria - Taiho Pharmaceutical
Chikashi Ishioka
Honoraria - Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical
Hiroshi Furukawa
No relevant relationships to disclose